Can J&J's Invokana reap the benefits of Lilly and BI's new cardiac data? Its CFO thinks so

Analysts have speculated that Eli Lilly ($LLY) and Boehringer Ingelheim's SGLT2 rivals may see their own sales rise, thanks to data showing the pair's med, Jardiance, reduced the combined risk of heart attack, stroke and death from cardiovascular causes in high-risk Type 2 diabetes patients. Johnson & Johnson ($JNJ), which makes challenger Invokana, agrees. "We do think there's a positive effect to the overall class as a result of the cardiovascular data that Lilly shared," company CFO Dominic Caruso said on the company's Q3 conference call on Tuesday. The New Jersey pharma giant should have its own data by 2017 showing whether Invokana can replicate Jardiance's cardiac benefit. More